Study aim: The aim of this study is to evaluate the effect of adding oral minoxidil to standard anti-inflammatory therapy in the treatment of patients with lichen planoplaris Design: This study is a randomized clinical trial and patients are randomly divided into two groups of methotrexate and oral minoxidil with methotrexate by random allocation software Settings and conduct: Two groups of 17 people are selected from the patients referred to the dermatology clinic. After the patient is examined for 3 (LPPAI score, photography and dermoscopy) and the results are recorded, treatment begins Participants/Inclusion and exclusion criteria: Inclusion criteria include patients between the ages of 18 and 65 who have just been diagnosed and have not yet received treatment. Patients who have previously been treated and whose disease is still active according to clinical and dermoscopic criteria Patients should have discontinued any previous systemic medication 1 month prior to enrollment and should not use any systemic or topical medications at the time of the study. Conditions for not entering the study are: Pregnancy or breastfeeding 2-leukocytes <3000 3-platelets <100000 4-Hemoglobin <9 5. Liver enzymes more than 2 times the reference limit 6. Positive hepatitis V tests 7- History of cardiovascular diseases and hypotension 8- History of arrhythmia (non-sinus rhythm in ECG) Intervention groups: After obtaining the consent, one group will be treated with 15 mg of methotrexate weekly and the other group will be treated with 1 mg of minoxidil tablets with 15 mg of methotrexate for 6 months Main outcome variables: Lichen planoplaris disease activity index is calculated and standard and dermoscopic general imaging is performed in all patients in months 0, 2, 4 and 6, then the results of the two groups before and after treatment are compared